首个重度斑秃全身疗法的新型靶向药——巴瑞替尼  

First-in-class targeted agent for severe alopecia areata:baricitinib

作　　者：李丹[1] 赵晓娟[1] 赵永红[1] 孙倩[1] 何文娟[1] 刘秀菊[1] LI Dan;ZHAO Xiao-juan;ZHAO Yong-hong;SUN Qian;HE Wen-juan;LIU Xiu-ju(Department of Pharmacy,the Second Hospital of HeBei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院药学部,石家庄050000

出　　处：《临床药物治疗杂志》2022年第12期56-59,共4页Clinical Medication Journal

摘　　要：巴瑞替尼是美国食品药品管理局(FDA)首次批准用于斑秃全身疗法的JAK抑制剂靶向药物,由礼来和因塞特公司共同研发,于2022年6月13日在美国获批上市。两项临床研究显示,巴瑞替尼组治疗36周时的脱发严重程度工具评分≤20分(第36周时头皮毛发覆盖率至少达到80%)的患者比例与安慰剂组的差异具有统计学意义,巴瑞替尼治疗重度斑秃患者疗效显著。巴瑞替尼治疗的安全性良好,常见不良反应包括感染、痤疮、高脂血症、肌酸磷酸激酶升高等。巴瑞替尼将会满足重度斑秃患者的重大医疗需求。Baricitinib,the first JAK inhibitor targeted drug approved by the U.S.Food and Drug Administration(FDA)for systemic therapy of alopecia areata,was jointly developed by Lilly and Incyte.Baricitinib was approved by FDA on June 13,2022.Two clinical trials showed a statistically significant difference between the proportion of patients in the baricitinib group with a Severity of Alopecia Tool score of 20 or less at week 36(at least 80%scalp hair coverage at week 36)and the placebo group in severe alopecia areata.Baricitinib showed significant efficacy in the treatment of severe alopecia areata.Baricitinib has a good safety profile.Common adverse events include infection,acne,hyperlipidemia,and elevated creatine phosphokinase.Baricitinib will meet a significant medical need for patients with severe alopecia areata.

关 键 词：巴瑞替尼 斑秃 JAK抑制剂 

分 类 号：R986[医药卫生—药品]